Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir
The publication (https://science.sciencemag.org/content/366/6470/1255) describes the optimization, using Codexis’ proprietary CodeEvolver® protein engineering platform, of five enzymes for the synchronized synthesis of a complex pharmaceutical candidate in very few steps, starting from simple raw materials. The process demonstrates the utility of engineered enzymes in coordinated cascades to perform highly complex chemistry for previously difficult-to-produce molecules.
“The synthesis of nucleoside analogs via traditional chemistry methods can be particularly difficult and inefficient,” said
“We are very excited to build on our longstanding collaboration with
To the extent that statements contained in this press release are not descriptions of historical facts regarding
LHA Investor Relations
Source: Codexis, Inc.